🇧🇷Brazil
Incorrect MTM Billing Codes Leading to Zero Reimbursement
1 verified sources
Definition
Pharmacies submit claims for additional MTM service time using CPT code 99607 with zero dollar amounts, resulting in no reimbursement despite compliance requirements to bill correctly. Claims are processed in 'pay' status but pharmacies receive $0, causing lost revenue on documented service units. This occurs systemically in state Medicaid programs requiring accurate coding for follow-up minutes.
Key Findings
- Financial Impact: $34-$130 per unbilled unit (based on service level rates)
- Frequency: Per claim submission - recurring with each MTM service exceeding initial 15 minutes
- Root Cause: Mandatory submission of zero-dollar claims for add-on codes under Medicaid rules without corresponding reimbursement
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Retail Pharmacies.
Affected Stakeholders
billing specialists, pharmacists, pharmacy managers
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
Medicare Fraud Risk from Unbilled Parallel MTM Services
Full service value plus fraud penalties/repayments
Overcharging MTM Services Beyond State-Regulated Amounts
Refunds plus potential fines under Wis. Stat. § 49.688(5)(a)
Denied MTM Claims Due to New vs Established Patient Coding Errors
$52-$148 per denied CMR/A service
HRSA Audit Failures and Required Repayments for Diversion/Duplicate Discounts
$Repayment of full discounts plus potential civil monetary penalties per audit
Excess Labor and Overtime from Manual Compliance and Documentation Tasks
$1,000–$6,000 per store per month in additional labor and overtime associated with controlled‑substance record‑keeping and reconciliation
Delayed Reimbursement from Holds and Rejections on Controlled Substance Claims
$500–$4,000 per store per month in financing cost of delayed cash and staff time for claims follow‑up related to controlled substances